CENTRAL TRUST Co Has $68,000 Position in DaVita Inc. (NYSE:DVA)

CENTRAL TRUST Co lessened its stake in shares of DaVita Inc. (NYSE:DVA) by 25.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 415 shares of the company’s stock after selling 140 shares during the period. CENTRAL TRUST Co’s holdings in DaVita were worth $68,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. SG Americas Securities LLC lifted its holdings in shares of DaVita by 196.9% during the first quarter. SG Americas Securities LLC now owns 29,733 shares of the company’s stock worth $4,105,000 after buying an additional 19,719 shares during the last quarter. Bessemer Group Inc. raised its stake in DaVita by 2,335.6% during the 1st quarter. Bessemer Group Inc. now owns 10,741 shares of the company’s stock valued at $1,483,000 after purchasing an additional 10,300 shares during the last quarter. Forsta AP Fonden boosted its holdings in DaVita by 50.3% in the 1st quarter. Forsta AP Fonden now owns 23,600 shares of the company’s stock valued at $3,258,000 after purchasing an additional 7,900 shares during the period. Sei Investments Co. grew its position in DaVita by 21.3% in the 1st quarter. Sei Investments Co. now owns 41,952 shares of the company’s stock worth $5,790,000 after purchasing an additional 7,371 shares during the last quarter. Finally, BOKF NA increased its holdings in shares of DaVita by 286,550.0% during the 1st quarter. BOKF NA now owns 5,733 shares of the company’s stock worth $790,000 after purchasing an additional 5,731 shares during the period. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 2.7 %

DVA opened at $156.99 on Monday. The firm has a market cap of $13.77 billion, a price-to-earnings ratio of 17.84, a PEG ratio of 0.93 and a beta of 0.87. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16. The firm’s 50-day simple moving average is $158.09 and its 200-day simple moving average is $145.67. DaVita Inc. has a twelve month low of $75.47 and a twelve month high of $168.50.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.47 by $0.12. The company had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company’s revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the business posted $2.08 earnings per share. Equities research analysts anticipate that DaVita Inc. will post 9.99 EPS for the current fiscal year.

Insider Transactions at DaVita

In related news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Michael David Staffieri sold 9,539 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the transaction, the chief operating officer now directly owns 241,945 shares in the company, valued at $36,299,008.35. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 173,482 shares of company stock worth $27,387,069. Insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DVA. Truist Financial increased their target price on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. UBS Group raised their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Bank of America boosted their price objective on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Finally, TD Cowen raised their target price on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, DaVita currently has an average rating of “Hold” and an average target price of $159.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.